Three axes, one motor neuron.
ALS converges on mitochondrial dysfunction (energetic collapse in motor neurons), proteostasis failure (TDP-43, SOD1, FUS aggregation), and neuroinflammation (microglial activation). The PD pipeline's MITO and PROT blends were designed for the same biology — different cell type, same machinery. Atlas Bio's ALS program tests whether the mechanism-anchored cross-walk holds.
PD blends, ALS dosing, slow-progressor cohort.
| Component | Mechanism | Cross-walk source |
|---|---|---|
| ALS-MITO | Mitochondrial bioenergetics | PD-MITO-02 (re-dosed) |
| ALS-PROT | Proteostasis / aggregate clearance | PD-PROT-04 (re-dosed) |
| ALS-NF (mod) | Neuroinflammation modifier | PD-NF-01 (reduced dose, motor-axis bias) |
Cross-walk dosing logic and the slow-progressor enrichment criteria are gated. Gated
Slow-progressor enrichment to read the signal.
ALS trials fail when fast-progressors dilute signal. The Atlas Bio design enriches for slow-progressors (ALSFRS-R slope < 0.5/month for the 3 months prior to screening). Primary endpoint is slope-of-slope (acceleration), not raw ALSFRS-R. NfL (serum neurofilament light) is the biomarker primary; ALSFRS-R is clinical primary.
Inclusion criteria, NfL thresholds, and the slope-of-slope statistical pre-specification are gated. Gated
Same stack, every indication.
- M2 · Pre-Registration — SHA-256 locking before readout.
- M1 · IBC Reasoning — 19-agent audit of cross-walk plausibility from PD to ALS.
- M3 · Cross-Trial Validation — mechanism-anchored dose-adjustment when re-fitting PD blends for ALS.
- M4 · RWE Pipelines — ClinicalTrials.gov, PubMed, FDA, EDGAR, patient-reported feeds.
Want the full ALS protocol?
The abstract above is open. Cross-walk dosing matrix, slow-progressor enrichment criteria, NfL thresholds, the slope-of-slope pre-registration, and the Phase IIa trial design are available to verified ALS clinicians, researchers, and sponsors under MNDA. Contact management to begin the access request.
Contact management →